Sign in Subscribe

Topic

PGx news

A collection of 42 issues

Wall Street Journal Discusses Predispositional Personal Genome Sequencing, PGx

A recent article by Laura Landro in the Wall Street Journal titled “Why Knowing Your Genetic Data Can Be a Tricky Proposition” discusses the benefits and complications of Predisposition Personal Genome Sequencing (PPGS) and the Personal Genome Sequencing Outcomes, or PeopleSeq consortium. PPGS is preemptive genome sequencing of apparently healthy

Race and Pharmacogenetics discussed in the New England Journal of Medicine

The authors of a new Perspective in the New England Journal of Medicine (“Will precision medicine move us beyond race?”) focus on the potential pitfalls of using race based categories as proxies for pharmacogenetic variants. Self-identified race may not predict genotype or drug response in individual patients and the use

Pharmacogenetics in Scientific American

Dina Fine Maron discusses pharmacogenetics and pharmacogenomics (PGx) in a new video and article titled “A Very Personal Problem” in this week’s issue of Scientific American. In that article, Fine Maron describes the science of PGx and tells the personal stories of two pediatric patients who received care at

European Union awards €15 million to U-PGx consortium

The European Union H2020 programme has awarded a €15 million grant to the Ubiquitous Pharmacogenomics (U-PGx) consortium for an international pharmacogenomics research and implementation project. The aim of the U-PGx consortium is to make actionable pharmacogenomic data and effective treatment optimization accessible to every European citizen. The objective of the

DPYD testing saves money as well as prevents fluoropyrimidine toxicity

A recent article [PMID: 26573078] and editorial [PMID: 26644533] in The Journal of Clinical Oncology looked at prospective testing for DPYD *2A and prevention of grade 3 or higher toxicity. The study examined a large number of patients (n=2,038) and identified 22 carriers of DPYD *2A who then

The Wall Street Journal Discusses PGx

An article in the Wall Street Journal this week by Health Editor Melinda Beck called “Is Your Medicine Right for Your Metabolism?” discusses the current state of pharmacogenetics and obstacles to implementation of pharmacogenetics (PGx) in routine clinical care. The article and an accompanying video explain that variations in enzymes

Integrating PGx throughout the Drug Development Process

Nelson, et al. argue for integrating more pharmacogenomic research into drug screening and the pre-approval process, with benefits for patient outcomes and drug development. Their article “The genetics of drug efficacy: opportunities and challenges,” published this week in Nature Reviews Genetics reviews currently known associations of genetic variants with drug

The Precision Medicine Initiative: Consultative PGx and Data Sharing at Stanford University

On February 25th, one year after the announcement of the Precision Medicine Initiative (PMI), the White House hosted the Precision Medicine Summit. A White House press release described how various public and private groups will be taking steps to advance the goals of the PMI. As part of the PMI

EPIC Integrates Genelex's Pharmacogenomics Decision Support System into Electronic Health Records

On Feb 23rd, Pharmagenomics (PGx) testing company Genelex announced enhanced connection with Epic, the most widely used electronic health record (EHR) system in US. With this new connectivity, healthcare systems and providers using Epic EHRs will be able to use Genelex's YouScript Precision Prescribing software to better identify

A Study of the Transcriptomic Variation Affecting Pharmacogenes

In an effort to capture differences in the expression of pharmacogenes between individuals and between tissue types and to characterize novel pharmacogene splice variants, researchers conducted a transcriptomic analysis of 389 pharmacologically important genes in liver, kidney (cortex), heart (left ventricle), and adipose tissue from 139 individuals as well as